Dariusz Rozkiewicz
Overview
Explore the profile of Dariusz Rozkiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rozkiewicz D, Hermanowicz J, Kwiatkowska I, Krupa A, Pawlak D
Molecules
. 2023 Mar;
28(5).
PMID: 36903645
In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell...
2.
Rozkiewicz D, Hermanowicz J, Tankiewicz-Kwedlo A, Sieklucka B, Pawlak K, Czarnomysy R, et al.
J Enzyme Inhib Med Chem
. 2020 Sep;
35(1):1697-1711.
PMID: 32912025
Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and...
3.
Tankiewicz-Kwedlo A, Hermanowicz J, Surazynski A, Kwedlo W, Rozkiewicz D, Pawlak K, et al.
Curr Pharm Biotechnol
. 2016 Dec;
18(2):127-137.
PMID: 27903235
Background: Cancer patients treated with alkylating agents and radiotherapy are exposed to high level of reactive oxygen species (ROS) in tissues. ROS can involve superoxide free radicals, peroxynitrite, singlet oxygen,...
4.
Pawlak K, Rozkiewicz D, Mysliwiec M, Pawlak D
Cytokine
. 2013 Mar;
62(1):75-80.
PMID: 23490418
Background: YKL-40 is a new biomarker of inflammation, which is expressed by several cell types of the immune system. The aim of the present study was to evaluate plasma YKL-40...